

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2024

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**” or “**Genertec Universal Medical**”), together with its subsidiaries (the “**Group**”), for the third quarter ended 30 September 2024.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first three quarters of 2024, the Group has been diligently enhancing the high-quality development of its healthcare business. The business performance has been stable and improving, with substantial progress in key areas. For the nine months ended 30 September 2024, the revenue of the Group decreased slightly by approximately 1.2% as compared with the corresponding period of 2023, while the profit for the period attributable to owners of the parent increased by approximately 5.1% as compared with the corresponding period of 2023. Furthermore, according to the Hang Seng Indexes Company Limited’s quarterly adjustment results of the Hang Seng Series Index released on 16 August 2024, the industry classification of the Group under the Hang Seng Index has been adjusted from “Financials” to “Healthcare”, and the Group has been officially included in the Hang Seng Healthcare Index. This adjustment of industry classification originates from the significant growth of the Group’s performance in the healthcare sector in recent years and also represents the recognition by Hang Seng Indexes Company Limited of Genertec Universal Medical’s development potential in the healthcare sector. It will further enhance Genertec Universal Medical’s visibility in the capital market, thereby effectively assisting the listed company in carrying out market value management related work, and enhancing the development quality as a listed company controlled by a central state-owned enterprise.

In respect of integrated healthcare business, focusing on the primary goals of “Comfortable environment, Top-notch services, Advanced technology and Efficient operation”, the Group continued to empower the development of the hospitals run by state-owned enterprises and improve the operation efficiency and effectiveness. The medical institutions affiliated with the Group performed well in the first three quarters of 2024: outpatient and emergency visits increased by approximately 4.9% as compared with the corresponding period of 2023, while the number of discharged patients increased by approximately 6.7% as compared with the corresponding period of 2023. The average length of hospital stay has been reduced to 9.8 days, with the bed utilisation rate maintained at a high level of approximately 90%, indicating a continuous improvement in operational efficiency.

In respect of specialties and healthcare technology business, the Group focuses on core medical resources, adheres to the “dual-wheel drive” of internal development and external expansion, and gradually builds a big health ecosystem to provide a technology engine for innovative development and a new profit growth point for the Company, while improving the quality and efficiency of the service. Currently, all projects within this segment are progressing as planned, including business expansion and capacity building, thus further strengthening the foundation for industrialisation of this segment. For the nine months ended 30 September 2024, the revenue from the life cycle management of medical equipment business amounted to RMB423.3 million, representing an increase of approximately 515.1% as compared with the corresponding period of 2023, with the profit for the period of RMB49.6 million, representing an increase of approximately 263.8% as compared with the corresponding period of 2023. By the end of September, the Group has completed the acquisition and integration of Shandong University of Traditional Chinese Medicine Affiliated Ophthalmic Hospital (山東中醫藥大學附屬眼科醫院) and Shan Dong JB SoftInfo Technology Co., Ltd. (山東青島軟通股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 831718). In addition, other acquisition projects for specialised medical institutions and health technology companies are also progressing smoothly.

In respect of finance business, the Group adheres to its functional positioning of serving the real economy and supporting the development of its core business, promoting the integration of industry and finance and to ensure the safe and stable development of finance business. On the cost side, by closely monitoring the market trends and ensuring reasonable liquidity and a stable debt maturity structure, the Group actively utilised various financing tools both domestically and internationally to effectively control overall financing costs. As at 30 September 2024, interest-earning assets continued to increase as compared with the middle of 2024, with steady improvement in net interest margin and net interest spread. Asset quality still remained at a good level, and the provision coverage remained prudent.

The Company hereby reminds investors that the above unaudited operation summary for the third quarter ended 30 September 2024 was prepared based on the Group’s internal figures and management accounts which have not been reviewed or audited by the auditors of the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 31 October 2024

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.